• Complicated skin/skin structure infections, complicated intra-abdominal infections, or community-acquired bacterial pneumonia caused by susceptible bacteria (should only be used when alternative treatments are not suitable; should NOT be used for diabetic foot infections).

Contraindicated in:

• Hypersensitivity
• Diabetic foot infections
• Hospital-acquired or ventilator-associated pneumonia
• Pedi: Children.

Use Cautiously in:

• Complicated intra-abdominal infections due to perforation
• Severe hepatic impairment (↓ maintenance dose recommended)
• OB: Use during pregnancy only if potential maternal benefit outweighs potential fetal risk; may cause permanent teeth discoloration and suppress bone growth in fetus, especially when used during 2nd or 3rd trimester
• Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant
• Geri: Older adults may be more sensitive to adverse effects.

Derm: STEVENS-JOHNSON SYNDROME (SJS).

Endo: hyperglycemia, hypoglycemia.

F and E: hypocalcemia, hyponatremia.

GI: nausea, vomiting, ↑ liver enzymes, anorexia, CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), dry mouth, jaundice, PANCREATITIS.

GU: ↑ serum creatinine.

Hemat: hypofibrinogenemia.

Local: injection site reactions.

Neuro: dysgeusia, somnolence.

Resp: pneumonia.

Misc: DEATH, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS).

Drug-Drug:

• May ↓ the effectiveness of hormonal contraceptives.
• Effects on warfarin are unknown; monitoring recommended.
• May ↑ trough levels and risk of toxicity of calcineurin inhibitors, including cyclosporine and tacrolimus.

(Generic available)

• Lyophilized powder for injection: 50 mg/vial;

• IV (Adults): 100 mg initially, then 50 mg every 12 hr for 5–14 days (skin/skin structure infections and intra-abdominal infections) or 7–14 days (pneumonia).

Tygacil

• Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.

• Resolution of infection.

Spectrum:

• Active against the following gram-positive bacteria: Enterococcus faecalis(vancomycin-susceptible strains only), Staphylococcus aureus (methicillin-sensitive and methicillin-resistant strains), Streptococcus agalactiae, Streptococcus anginosus, Streptococcus pneumoniae (penicillin-susceptible isolates), and Streptococcus pyogenes.
• Also active against these gram-negative organisms: Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Legionella pneumophila, Klebsiella oxytoca, and Klebsiella pneumoniae.
• Additionally active against the following anaerobes: Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus micros.

Therapeutic Classification: anti-infectives

Pharmacologic Classification: glycylcyclines

Absorption: IV administration results in complete bioavailability.

Distribution: Widely distributed with good penetration into gall bladder, lung, and colon.

Metabolism/Excretion: Minimal metabolism; primary route of elimination is biliary/fecal excretion of unchanged drug and metabolites (59%), 33% renal (22% unchanged).

Half-life: 27.1 hr (after 1 dose); 42.4 hr after multiple doses.

(plasma concentrations)

• Advise patient that full course of therapy should be completed, even if feeling better. Skipping doses or not completing full course of therapy may result in decreased effectiveness and increased risk of bacterial resistance.
• Instruct patient to notify health care professional if fever and diarrhea develop, especially if stool contains blood, pus, or mucus. Advise patient not to treat diarrhea without consulting health care professional.
• Advise patient to report the signs of superinfection (black, furry overgrowth on the tongue, vaginal itching or discharge, loose or foul-smelling stools). Skin rash, pruritus, and urticaria should also be reported.
• Rep: Advise females of reproductive potential to use a nonhormonal method of contraception while taking tigecycline and until next menstrual period. Use during the second and third trimesters may cause permanent yellow-gray-brown discoloration of the teeth and reversible inhibition of bone growth. Advise patient to avoid breastfeeding during and for 9 days after last dose of tigecycline. Advise patient to notify health care professional if pregnancy is planned or suspected.

tye-gi-SYE-kleen

NDC Code^*

• 0008- Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
  • 0008-4990- Tygacil
    • 0008-4990-02- 10 VIAL, SINGLE-USE in 1 CARTON (0008-4990-02) > 50 mL in 1 VIAL, SINGLE-USE (0008-4990-01)

• 0008- Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
  • 0008-4990- Tygacil
    • 0008-4990-20- 10 VIAL, SINGLE-USE in 1 CARTON (0008-4990-20) > 50 mL in 1 VIAL, SINGLE-USE (0008-4990-19)

• 0008- Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
  • 0008-4994- Tygacil
    • 0008-4994-02- 10 VIAL, SINGLE-USE in 1 CARTON (0008-4994-02) > 50 mL in 1 VIAL, SINGLE-USE (0008-4994-01)

• 0008- Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
  • 0008-4994- Tygacil
    • 0008-4994-20- 10 VIAL, SINGLE-USE in 1 CARTON (0008-4994-20) > 50 mL in 1 VIAL, SINGLE-USE (0008-4994-19)

• 0781- Sandoz Inc
  • 0781-3481- Tigecycline
    • 0781-3481-92- 10 VIAL, SINGLE-DOSE in 1 CARTON (0781-3481-92) > 10 mL in 1 VIAL, SINGLE-DOSE

• 16729- Accord Healthcare Inc.
  • 16729-364- TIGECYCLINE
    • 16729-364-68- 10 VIAL, SINGLE-DOSE in 1 CARTON (16729-364-68) > 10 mL in 1 VIAL, SINGLE-DOSE (16729-364-03)

• 55150- AuroMedics Pharma LLC
  • 55150-228- Tigecycline
    • 55150-228-10- 10 VIAL in 1 CARTON (55150-228-10) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL

• 60505- Apotex Corp
  • 60505-6098- Tigecycline
    • 60505-6098-1- 10 VIAL, SINGLE-USE in 1 CARTON (60505-6098-1) > 5 mL in 1 VIAL, SINGLE-USE

• 63323- Fresenius Kabi USA, LLC
  • 63323-960- Tigecycline
    • 63323-960-10- 10 VIAL, SINGLE-DOSE in 1 CARTON (63323-960-10) > 5 mL in 1 VIAL, SINGLE-DOSE

• 70121- Amneal Biosciences LLC
  • 70121-1647- Tigecycline
    • 70121-1647-7- 10 VIAL in 1 CARTON (70121-1647-7) > 5 mL in 1 VIAL (70121-1647-1)